Assessment of cancer cost at the international level: Challenges and methodological approaches;L'évaluation des coûts du cancer au niveau international: Défis et approches méthodologiques

Bulletin du Cancer

Volumn 90, Issue 11, 2003, Pages 1016-1023

  Crott, Ralph ^a  

^a EORTC DATA CENTER   (Belgium)

Author keywords

Cancer; Cost; National health accounts

Indexed keywords

ANALYTIC METHOD; ANALYTICAL ERROR; ARTICLE; CANCER; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DATA BASE; EVALUATION; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HUMAN; INFORMATION PROCESSING; OUTCOMES RESEARCH; PATIENT CARE; RESOURCE ALLOCATION; STANDARD; STATISTICAL ANALYSIS; TECHNIQUE;

COSTS AND COST ANALYSIS; DATABASES, FACTUAL; HEALTH EXPENDITURES; HUMANS; NEOPLASMS; WORLD HEALTH;

EID: 0346218224     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Borella L, Finkel S, Crapeau N, Peuvrel P, et al. Volume et coût de la prise en charge hospitalière du cancer en France en 1999. Bull Cancer 2002 ; 8 : 809-21.
2. Huskamp HA, Newhouse JP. Future directions for the National Health Accounts. Health Care Financing Review 1999 ; 21 : 5-14.
3. OECD. The state of implementation of the OECD manual: a system of health accounts (SHA) in OECD member countries. 2001. OECD Health Policy Unir, 10 juin 2001.
4. OECD. A system of health accounts (SHA). Paris : OECD, mai 2000.
5. Health Canada. Economic burden of illness in Canada, 1998. Ottawa : Policy Research Division, Strategic policy Directorate, Population and Public Health Branch, 2002.
6. Polder JJ, Takken J, Meerding WJ, Kommer GJ, Stokx LJ. Kosten van Ziekten in Nederland. Bilthoven, The Netherlands : Cenrrum voor Volksgezondheid Toekomst Verkenningen, RIVM, 2002.
7. OECD. Health Data 2002. Paris : OECD-Credes, 2002.
8. Paris V, Renaud T, Sermet C. Des comptes de la santé par pathologie : un prototype sur l'année 1998. Paris : Rappott Credes 1480, 2003/05.
9. Brown ML, Riley GF, Schusslet N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 2002 ; 40 (Suppl. IV). 104-17.
10. Hodgson TA, Cohen AJ. Medical expenditures for major diseases, 1995. Health Care Financing Review 1999 ; 21 : 119-64.
11. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death from elderly cancer patients by stage at diagnosis. Med Care 1995 ; 33 : 828-40.
12. Brown ML, Riley GF, Potosky AL, Etzioni R. Obtaining long-term disease specific costs of care. Med Care 1999 ; 37 : 1249-59.
13. Hadley J, Polsky D, Mandelblarr J, Mitchell JM, et al. An exploratory instrumental variable analysis of the outcomes of localized breast cancer treatments in a Medicare population. Health Economics 2003 ; 12 : 171-86.
14. Barlow WE, Taplin SH, Yoshida CK, Buist DS, Seger D, Brown M. Cost comparison of mastectomy versus breast-conserving therapy for early-stage breast cancer. J Natl Cancer Inst 2001 ; 93 : 447-55.
15. Website de l' EORTC à l'adresse www.eortc.be.
16. Neymark N, Gorlia T, Adriaenssen I, Baron B, Piccatt M. Cost effectiveness of paclitaxel/cisplatin compared to cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium. PharmacoEconomics 2002 ; 20 : 485-97.
17. Calhoun E, Chang CH, Welshman EY, Fishman DA, et al. Evaluating the total costs of chemotherapy-induced toxicity : results from a pilot study with ovarian cancer patients. The Oncologist 2001 ; 6 : 441-5.